Patents Examined by Shulamith H. Shafer
  • Method of reducing titers of antibodies specific for a therapeutic agent
    Patent number: 9592247
    Abstract: The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: March 14, 2017
    Assignee: Duke University
    Inventors: Priya S. Kishnani, Suhrad G. Banugaria, Dwight D. Koeberl, Sean N. Prater
  • Antibody capable of specifically recognizing transferrin receptor
    Patent number: 9593165
    Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: March 14, 2017
    Assignees: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.
    Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
  • Fusion tags and expression vector system for the expression of human parathyroid hormone (rhPTH)
    Patent number: 9580488
    Abstract: The present invention provides for fusion tags of 20 to 40 amino acids having a sequence as given in FIG. 1, fusion tags sharing homology with these fusion tags, or hybrid fusion tags comprising sequences of FIG. 1. The invention further provides an expression vector system comprising a fusion tag of the invention, and a process of obtaining recombinant human parathyroid hormone by using the fusion tags and the expression vector system of the invention.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 28, 2017
    Inventors: Siddamadappa Chandrashekaran, Venkat Hemalatha
  • Anti-histone therapy for vascular necrosis in severe glomerulonephritis
    Patent number: 9580495
    Abstract: Severe glomerulonephritis involves cell necrosis as well as NETosis, programmed neutrophil death leading to expulsion of nuclear chromatin and neutrophil extracellular traps (NETs). Histones released by neutrophils undergoing NETosis killed glomerular endothelial cells, podocytes, and parietal epithelial cells. This was prevented by histone-neutralizing agents anti-histone IgG, activated protein C and heparin. Histone toxicity on glomeruli was TLR2/4-dependent. Anti-GBM glomerulonephritis involved NET formation and vascular necrosis. Pre-emptive anti-histone IgG administration significantly reduced all aspects of glomerulonephritis, including vascular necrosis, podocyte loss, albuminuria, cytokine induction, recruitment and activation of glomerular leukocytes and glomerular crescent formation.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: February 28, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Santhosh V. R. Kumar, Hans-Joachim Anders
  • Melanoma antigen peptide and uses thereof
    Patent number: 9573975
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: February 21, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, François Lang, Mathilde Bobinet, Anne Rogel
  • Extracellular vesicles comprising recombinant lysosomal transmembrane protein
    Patent number: 9566314
    Abstract: The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from cystinosis.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: February 14, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jess Thoene, Jeffrey Innis
  • Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing
    Patent number: 9561275
    Abstract: The present invention provides an immunoconjugate having the formula: T-c-En-c-Fcn or T-c-Fcn-c-En; wherein, T is a single chain variable portion fragment of a monoclonal antibody (scFv) directed to a target protein, polypeptide, or fragment thereof, which is highly expressed on cancer cells; E is two or more foreign immunogenic CD8+ T cell antigenic epitopes; c is a peptide or polypeptide fragment thereof, capable of being cleaved by a specific protease; and Fc is two or more Fc portions of an IgG antibody. Nucleic acid sequences encoding the same and vectors containing said nucleic acid sequences are also provided. Methods of making the immunoconjugate, along with methods of making target cells susceptible to CTL mediated cell killing, and methods for treatment of cancers are also provided.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: February 7, 2017
    Assignee: The Johns Hopkins University
    Inventors: Chien-Fu Hung, T. C. Wu
  • Immunogenic compositions against human progastrin peptides
    Patent number: 9550806
    Abstract: Immunogens against human extended-progastrin species comprise (A) a mimetic peptide comprised of (i) the amino acid sequence of a progastrin or a N- and/or C-terminal processed species of a progastrin joined to (ii) a 7 amino-acid spacer coupled to (B) an immunogenic carrier. Illustrative of the mimetic peptide/spacer combination are a 21 amino-acid peptide (SEQ ID NO.: 1) and other, related polypeptides (SEQ ID NOs.: 2-5). Pharmaceutical compositions containing such an immunogen display improved immunological properties, including the induction of effective antibody levels shortly after the administration of an initial course of immunogen. Levels of antibody thus elicited stay elevated for several months and readily elevate to higher levels upon subsequent boosting by a single injection of immunogen.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 24, 2017
    Assignee: ONKOLOGIX LTD.
    Inventors: Richard Ascione, Shengmei Qi, Bin Wang
  • Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
    Patent number: 9545442
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: January 17, 2017
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Use of antibodies for detection of IL-10
    Patent number: 9540436
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: January 10, 2017
    Assignee: BIOTEST AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
  • Neutralizing antibodies and methods of use thereof
    Patent number: 9540444
    Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: January 10, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Greg Elson, Olivier Leger
  • Vaccine capable of inducing formation of antibodies directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) in vivo
    Patent number: 9533030
    Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: January 3, 2017
    Assignee: AFFIRIS AG
    Inventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
  • Neutralizing antibodies and methods of use thereof
    Patent number: 9534049
    Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: January 3, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Greg Elson, Olivier Leger
  • Combination of an insulin and a GLP-1-agonist
    Patent number: 9526764
    Abstract: The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: December 27, 2016
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Ulrich Werner, Barbel Rotthauser
  • Pharmaceutical compositions comprising inhibitors of zinc-ZIP8-MTF1 as active ingredients for preventing or treating a joint disease
    Patent number: 9526782
    Abstract: The present invention relates to identification of Zinc-ZIP8-MTF1 axis that plays an important role to OA (osteoarthritis) pathogenesis process and a novel use thereof. According to the present invention, ZIP8 and MTF1 of the present invention increase in the expression in joint disease induced cells or cartilage tissue, and induce the expression of various matrix-degrading enzymes (e.g., MMP-3, MMP-9, MMP-12, MMP-13 and ADAMTS-5 etc.). In addition, when the expression of ZIP8 or MTF1 is inhibited in cells or tissues of animals (e.g., human, mouse), OA pathogenesis is inhibited. Therefore, the ZIP8 and MTF1 of the present invention may be applied to the diagnosis or prognosis of joint diseases, and may be used for the development of therapeutics for joint diseases using these.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: December 27, 2016
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jang-Soo Chun, Jin-Hong Kim
  • Antibody preparations
    Patent number: 9518110
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: December 13, 2016
    Assignee: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • Methods useful for vitamin D deficiency and related disorders
    Patent number: 9500661
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: November 22, 2016
    Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
    Patent number: 9493531
    Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: November 15, 2016
    Assignee: JYANT TECHNOLOGIES, INC.
    Inventor: James W. Lillard, Jr.
  • Low protein infant formula with increased essential amino acids
    Patent number: 9492498
    Abstract: The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: November 15, 2016
    Assignee: N.V. Nutricia
    Inventors: Johannes Bernard Van Goudoever, Eline Marleen Van Der Beek, Marieke Abrahamse-Berkeveld, Günther Boehm
  • Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
    Patent number: 9487571
    Abstract: Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Method of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: November 8, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Tao Ma